JP2023507142A5 - - Google Patents

Info

Publication number
JP2023507142A5
JP2023507142A5 JP2022537047A JP2022537047A JP2023507142A5 JP 2023507142 A5 JP2023507142 A5 JP 2023507142A5 JP 2022537047 A JP2022537047 A JP 2022537047A JP 2022537047 A JP2022537047 A JP 2022537047A JP 2023507142 A5 JP2023507142 A5 JP 2023507142A5
Authority
JP
Japan
Prior art keywords
tcr
mhc
antigen
cells
peptide complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507142A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065147 external-priority patent/WO2021126872A1/en
Publication of JP2023507142A publication Critical patent/JP2023507142A/ja
Publication of JP2023507142A5 publication Critical patent/JP2023507142A5/ja
Priority to JP2025169565A priority Critical patent/JP2026010019A/ja
Pending legal-status Critical Current

Links

JP2022537047A 2019-12-16 2020-12-15 多重特異性ｔ細胞受容体 Pending JP2023507142A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025169565A JP2026010019A (ja) 2019-12-16 2025-10-07 多重特異性ｔ細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962948691P 2019-12-16 2019-12-16
US62/948,691 2019-12-16
PCT/US2020/065147 WO2021126872A1 (en) 2019-12-16 2020-12-15 Multi-specific t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025169565A Division JP2026010019A (ja) 2019-12-16 2025-10-07 多重特異性ｔ細胞受容体

Publications (2)

Publication Number Publication Date
JP2023507142A JP2023507142A (ja) 2023-02-21
JP2023507142A5 true JP2023507142A5 (enExample) 2023-12-13

Family

ID=76476722

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537047A Pending JP2023507142A (ja) 2019-12-16 2020-12-15 多重特異性ｔ細胞受容体
JP2025169565A Pending JP2026010019A (ja) 2019-12-16 2025-10-07 多重特異性ｔ細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025169565A Pending JP2026010019A (ja) 2019-12-16 2025-10-07 多重特異性ｔ細胞受容体

Country Status (8)

Country Link
US (1) US20230272036A1 (enExample)
EP (1) EP4076510A4 (enExample)
JP (2) JP2023507142A (enExample)
KR (1) KR20220116458A (enExample)
CN (1) CN114828877A (enExample)
AU (1) AU2020404933A1 (enExample)
CA (1) CA3161826A1 (enExample)
WO (1) WO2021126872A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507843A (ja) * 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
WO2018075591A1 (en) * 2016-10-18 2018-04-26 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
CA3091954A1 (en) * 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh New ehv with inactivated ul18 and/or ul8

Similar Documents

Publication Publication Date Title
Münz Latency and lytic replication in Epstein–Barr virus-associated oncogenesis
Saha et al. Epstein-Barr virus–associated B-cell lymphomas: pathogenesis and clinical outcomes
US11305015B2 (en) Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
Feederle et al. A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus
van Zyl et al. Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice
Ma et al. Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response
King et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance
Kosinska et al. Combination of DNA prime–adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model
Ruiss et al. A virus-like particle-based Epstein-Barr virus vaccine
JP2019531745A5 (enExample)
Flaño et al. A mouse model for infectious mononucleosis
Osen et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity
Kamphorst et al. CD4 T-cell immunotherapy for chronic viral infections and cancer
Salnikov et al. The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape
JP2019502371A5 (enExample)
Full et al. T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor
CN112189018A (zh) 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
Takeda et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model
Zhang et al. GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies
Dai et al. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells
Forrest et al. NK cell memory to cytomegalovirus: implications for vaccine development
Fiedler et al. Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus
JP2022512538A5 (enExample)
Jiang et al. Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12
Gallez-Hawkins et al. Use of transgenic HLA A* 0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response